Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7964880 | 0.89 | PLA2G2A (1.00) | PLA2G2A | |
| SCHEMBL7965400 | 0.89 | PLA2G2A (0.81) | PLA2G2A | |
| SCHEMBL4317828 | 0.88 | PLA2G2A (1.00) | PLA2G2A | |
| SCHEMBL13484799 | 0.87 | PLA2G2A (1.00) | PLA2G2A | |
| SCHEMBL7953150 | 0.86 | PLA2G2A (1.00) | PLA2G2A | |
| SCHEMBL7962328 | 0.85 | PLA2G2A (1.00) | PLA2G2A | |
| SCHEMBL7962093 | 0.85 | PLA2G2A (1.00) | PLA2G2A | |
| SCHEMBL7953755 | 0.85 | PLA2G2A (1.00) | PLA2G2A | |
| SCHEMBL7952775 | 0.85 | PLA2G2A (0.82) | PLA2G2A | |
| SCHEMBL8926504 | 0.85 | PLA2G2A (0.77) | PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0620215-B1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | LILLY CO ELI (US) | 1999-08-18 | — | — | EP | claimed |
| EP-0620215-A1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | claimed |
| US-7666898-B2 | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors | ILYPSA, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20080051447-A1 | Treatment Of Hypercholesterolemia, Hypertriglyceridemia And Cardiovascular-Related Conditions Using Phospholipase-A2 Inhibitors | ILYPSA, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051447-A1 | Treatment Of Hypercholesterolemia, Hypertriglyceridemia And Cardiovascular-Related Conditions Using Phospholipase-A2 Inhibitors | ILYPSA, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080021049-A1 | Treatment Of Diet-Related Conditions Using Phospholipase-A2 Inhibitors Comprising Indoles And Related Compounds | ILYPSA, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021049-A1 | Treatment Of Diet-Related Conditions Using Phospholipase-A2 Inhibitors Comprising Indoles And Related Compounds | ILYPSA, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| US-6252084-B1 | THERAPY FOR SEPSIS SHOCK | ELI LILLY AND COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-0620215-B1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | LILLY CO ELI (US) | 1999-08-18 | — | — | EP | disclosed |
| EP-0620215-A1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | GPR119, INMT, PNLIP | PLA2G2A 246/4885 |
| US-20080021049-A1 | Treatment Of Diet-Related Conditions Using Phospholipase-A2 Inhibitors Comprising Indoles And Related Compounds | PLA2G12A, PLA2G4A, PLA2G2E | PLA2G2A 13/4885 |
| US-20080051447-A1 | Treatment Of Hypercholesterolemia, Hypertriglyceridemia And Cardiovascular-Related Conditions Using Phospholipase-A2 Inhibitors | PNLIP, PLA2G1B, PLA2G4A | PLA2G2A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.